Hansa Biopharma Future Growth
Future criteria checks 2/6
Hansa Biopharma is forecast to grow earnings and revenue by 44.1% and 47.3% per annum respectively. EPS is expected to grow by 49% per annum. Return on equity is forecast to be -84.7% in 3 years.
Key information
44.1%
Earnings growth rate
49.0%
EPS growth rate
| Biotechs earnings growth | 37.4% |
| Revenue growth rate | 47.3% |
| Future return on equity | -84.7% |
| Analyst coverage | Low |
| Last updated | 15 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 580 | -450 | -231 | -211 | 4 |
| 12/31/2025 | 365 | -531 | -354 | -339 | 4 |
| 12/31/2024 | 235 | -630 | -505 | -498 | 4 |
| 9/30/2024 | 189 | -655 | -700 | -700 | N/A |
| 6/30/2024 | 164 | -802 | -744 | -744 | N/A |
| 3/31/2024 | 166 | -845 | -738 | -738 | N/A |
| 12/31/2023 | 134 | -832 | -756 | -756 | N/A |
| 9/30/2023 | 114 | -856 | -697 | -693 | N/A |
| 6/30/2023 | 159 | -759 | -630 | -626 | N/A |
| 3/31/2023 | 148 | -678 | -583 | -579 | N/A |
| 12/31/2022 | 155 | -611 | -506 | -503 | N/A |
| 9/30/2022 | 139 | -626 | -509 | -509 | N/A |
| 6/30/2022 | 77 | -620 | -514 | -514 | N/A |
| 3/31/2022 | 55 | -583 | -493 | -491 | N/A |
| 12/31/2021 | 34 | -548 | -484 | -481 | N/A |
| 9/30/2021 | 22 | -491 | -464 | -461 | N/A |
| 6/30/2021 | 18 | -465 | -327 | -325 | N/A |
| 3/31/2021 | 14 | -431 | -291 | -290 | N/A |
| 12/31/2020 | 6 | -421 | -291 | -290 | N/A |
| 9/30/2020 | 3 | -426 | -270 | -269 | N/A |
| 6/30/2020 | 3 | -398 | -357 | -354 | N/A |
| 3/31/2020 | 3 | -381 | -358 | -354 | N/A |
| 12/31/2019 | 3 | -360 | -338 | -335 | N/A |
| 9/30/2019 | 4 | -330 | -320 | -317 | N/A |
| 6/30/2019 | 3 | -298 | -293 | -291 | N/A |
| 3/31/2019 | 4 | -274 | -264 | -262 | N/A |
| 12/31/2018 | 3 | -248 | -207 | -205 | N/A |
| 9/30/2018 | 3 | -216 | -179 | -176 | N/A |
| 6/30/2018 | 3 | -192 | N/A | -161 | N/A |
| 3/31/2018 | 3 | -178 | N/A | -150 | N/A |
| 12/31/2017 | 3 | -177 | N/A | -150 | N/A |
| 9/30/2017 | 3 | -161 | N/A | -148 | N/A |
| 6/30/2017 | 3 | -151 | N/A | -137 | N/A |
| 3/31/2017 | 3 | -136 | N/A | -121 | N/A |
| 12/31/2016 | 3 | -111 | N/A | -95 | N/A |
| 9/30/2016 | 4 | -97 | N/A | -83 | N/A |
| 6/30/2016 | 3 | -84 | N/A | -72 | N/A |
| 3/31/2016 | 3 | -76 | N/A | -67 | N/A |
| 12/31/2015 | 7 | -66 | N/A | -58 | N/A |
| 9/30/2015 | 5 | -60 | N/A | -50 | N/A |
| 6/30/2015 | 5 | -51 | N/A | -39 | N/A |
| 3/31/2015 | 4 | -34 | N/A | -29 | N/A |
| 12/31/2014 | 2 | -29 | N/A | -24 | N/A |
| 9/30/2014 | 2 | -21 | N/A | -19 | N/A |
| 6/30/2014 | 3 | -20 | N/A | -17 | N/A |
| 3/31/2014 | 3 | -19 | N/A | -14 | N/A |
| 12/31/2013 | 2 | -18 | N/A | -15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0RC7 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0RC7 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0RC7 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0RC7's revenue (47.3% per year) is forecast to grow faster than the UK market (3.5% per year).
High Growth Revenue: 0RC7's revenue (47.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0RC7 is forecast to be unprofitable in 3 years.